Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)

Autor: Neil, HA, DeMicco, DA, Luo, D, Betteridge, DJ, Colhoun, HM, Durrington, PN, Livingstone, SJ, Fuller, JH, Hitman, GA

OBJECTIVE: Rates of cardiovascular disease are highest in the elderly. Lipid-lowering statin therapy reduces the proportional risk as effectively in older patients as in younger individuals; however, limited data are available for elderly patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::299d728db6c66fdba4d4503ec9a99841
https://ora.ox.ac.uk/objects/uuid:cec71858-a2fd-44d6-9fb0-40d68f31b9fa

Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes

Autor: Waters, DD, Ho, JE, Boekholdt, SM, Demicco, DA, Kastelein, JJP, Messig, M, Breazna, A, Pedersen, TR

Publikováno v: Journal of the American College of Cardiology, vol 61, iss 2
Journal of the American College of Cardiology, 61(2), 148-152. Elsevier USA
Waters, DD; Ho, JE; Boekholdt, SM; Demicco, DA; Kastelein, JJP; Messig, M; et al.(2013). Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. Journal of the American College of Cardiology, 61(2), 148-152. doi: 10.1016/j.jacc.2012.09.042. UCSF: Retrieved from: http://www.escholarship.org/uc/item/5br5w8p9

Objectives: The purpose of this study was to compare the incidence of new-onset diabetes (NOD) with cardiovascular (CV) event reduction at different levels of NOD risk. Background: Statins reduce the number of CV events but increase the incidence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::db075d025e999ece53a4632355bb9645
https://escholarship.org/uc/item/5br5w8p9

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.

Autor: Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, Demicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH, Colhoun, Helen M, Betteridge, D John, Durrington, Paul, Hitman, Graham, Neil, Andrew, Livingstone, Shona, Charlton-Menys, Valentine

Publikováno v: Diabetes; Sep2011, Vol. 60 Issue 9, p2379-2385, 7p

Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)

Autor: Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Demicco DA, Fuller JH, CARDS Investigators

Publikováno v: American Journal of Kidney Diseases; Nov2009, Vol. 54 Issue 5, p810-819, 10p

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)

Autor: Neil HAW, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA

Publikováno v: Diabetes Care; Nov2006, Vol. 29 Issue 11, p2378-2384, 7p